EUCTR2010-024393-19-PL进行中（未招募）1 期
A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen, Inc.
- 入组人数
- 776
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Glucocorticoid-initiating subpopulation:
- •Men and women = 18 years of age who have initiated
- •Prednisone = 7.5 mg daily or its equivalent within 3 months prior to screening and are expected to be treated with oral glucocorticoids for a total of at least 6 months
- •- Glucocorticoid-continuing subpopulation:
- •Men and women = 18 years of age who are taking
- •Prednisone = 7.5 mg daily or its equivalent for = 3 months preceding screening and are expected to be treated with oral glucocorticoids for a total of at least 6 months.
- •4.1.2 Glucocorticoid-continuing subjects who are = 50 years of age will be required to have a BMD value equivalent to a T-score = -2.0 at the lumbar spine, total hip, or femoral neck; or a BMD value equivalent to a T-score = -1.0 at the lumbar spine, total hip, or femoral neck and with a history of osteoporotic fracture.
- •4.1.3 Men and women < 50 years old at the time of screening in both glucocorticoid-continuing and glucocorticoid-initiating subpopulations, will be required to have a history of osteoporotic fracture.
- •4.1.4 Ambulatory
- •4.1.5 At least two lumbar vertebrae from L1 through L4 and one hip must be evaluable by DXA (duplicate scans required)
- •4.1.6 Subject or subject’s legally acceptable representative has provided informed consent prior to any study specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 504
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 272
排除标准
- •Received other OP treatment or bone active treatment with the following guidelines:
- •Oral bisphosphonate use
- •- > 3 months cumulatively in the past 2 years, OR
- •- > 1 month in the past year, OR
- •Any use during the 3-month period prior to screening
- •Administration of intravenous bisphosphonate, fluoride or strontium for OP within the last 5 years
- •Parathyroid hormone (PTH) or PTH derivatives within the last year
- •Denosumab for OP at any time in the past
- •Administration of any of the following treatment within 3 months of screening:
- •Any selective estrogen receptor modulator (SERM) (estrogen agonist/ antagonist)
- •Anabolic steroids or testosterone
- •Systemic hormone replacement therapy
- •Calcitonin
- •Other bone active drugs including anti-convulsants (except
- •benzodiazepines) and heparin
- •Chronic systemic ketoconazole, androgens, adrenocorticotropic
- •hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors,
- •gonadotropin-releasing hormone agonists
- •Administration of any of the following biologic agents within 4 weeks prior to screening:
- •Anti alpha 4 integrin antibody (eg, natalizumab)
- •Anti CD4/CD8 T-cells (eg, alefacept)
- •Anti IL-12/IL-23 (eg, ustekinumab)
- •CTLA4 inhibitor (eg, abatacept)
- •IL1 receptor antagonist (eg, anakinra)
- •IL6 inhibitor (eg, tocilizumab)
- •Monoclonal antibody to CD20 (eg, rituximab)
- •TNF antagonist (eg, adalimumab, certolizumab, golimumab,
- •etanercept, infliximab)
- •Administering >1 biologic agent for the treatment of underlying
- •inflammatory disease
- •Subject has an active infection or history of infections as follows:
- •any active infection for which systemic anti-infectives were used
- •within 4 weeks prior to screening
- •a serious infection, defined as requiring hospitalization or
- •intravenous anti-infectives within 8 weeks prior to screening
- •recurrent or chronic infections or other active infection
- •Evidence of any of the following:
- •History of hyperthyroidism (stable on antithyroid therapy is allowed)
- •History of hypothyroidism (stable on thyroid replacement therapy is allowed)
- •History of hypo- or hyperparathyroidism
- •History of Addison disease
- •History of osteomalacia
- •History of osteonecrosis of the jaw
- •History of recent tooth extraction or other dental surgery within the prior 6 months
- •Invasive dental work planned in the next 2 years
- •History of Paget’s disease of bone
- •Other bone diseases which affect bone metabolism Abnormalities of the following per central laboratory reference ranges
- •Vitamin D deficiency (25[OH] vitamin D level < 20 ng/mL
- •[< 49.9 nmol/L]).
- •Hypercalcemia
- 另有 17 项未显示
研究者
相似试验
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of Denosumab Compared with Risedronate in Glucocorticoid-treated IndividualsGlucocorticoid-induced osteoporosisMedDRA version: 18.1Level: LLTClassification code 10031287Term: Osteoporosis steroid-inducedSystem Organ Class: 100000004859EUCTR2010-024393-19-DEAmgen, Inc.776
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Denosumab Compared with Risedronate in Glucocorticoid-treated IndividualsEUCTR2010-024393-19-BEAmgen, Inc.776
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Denosumab Compared with Risedronate in Glucocorticoid-treated IndividualsGlucocorticoid-induced osteoporosisMedDRA version: 20.0Level: LLTClassification code 10031287Term: Osteoporosis steroid-inducedSystem Organ Class: 100000004859EUCTR2010-024393-19-HUAmgen, Inc.776
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Denosumab Compared with Risedronate in Glucocorticoid-treated IndividualsGlucocorticoid-induced osteoporosisMedDRA version: 19.1Level: LLTClassification code 10031287Term: Osteoporosis steroid-inducedSystem Organ Class: 100000004859EUCTR2010-024393-19-DKAmgen, Inc.776
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Denosumab Compared with Risedronate in Glucocorticoid-treated IndividualsGlucocorticoid-induced osteoporosisMedDRA version: 14.1Level: LLTClassification code 10031287Term: Osteoporosis steroid-inducedSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-024393-19-FRAmgen, Inc.776